PARP1 deficiency mitigates amyloid pathology, neurodegeneration, and cognitive decline in a familial Alzheimer's disease model - PubMed
3 days ago
- #Alzheimer's Disease
- #PARP1
- #Amyloid Pathology
- Elevated PAR levels in CSF of MCI and AD patients indicate PARP1 activation in Alzheimer's disease.
- PARP1 inhibition reduces Aβ pathology, neurodegeneration, and cognitive decline in 5XFAD mice.
- Mechanisms include decreased APP and BACE1, altered γ-secretase, and enhanced Aβ degradation via neprilysin.